期刊文献+

抗病毒治疗HIV感染者/艾滋病患者并发高血压相关因素研究

Factors associated with hypertension in HIV/AIDS patients undergoing antiviral therapy
原文传递
导出
摘要 目的 了解规范接受抗病毒治疗(antiretroviral therapy,ART)的人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染/艾滋病患者并发高血压的相关因素。方法 采用病例对照研究方法,将并发高血压的HIV感染者/艾滋病患者作为病例组,按性别、年龄(±3岁) 1∶1匹配的216例未患高血压的HIV感染者/艾滋病患者作为对照组。收集两组患者的一般人口学资料、临床特征、炎症指标等因素,应用条件logistics回归分析发生高血压的相关因素。结果 吸烟(OR=5.03,95%CI:1.18-21.51)、体质量指数(body mass index, BMI)≥24.0kg/m^(2)(OR=3.55, 95%CI:1.28-9.83)、空腹血糖≥7.0 mmol/L (OR=5.47,95%CI:1.21-24.77)、肌酐(OR=1.01,95%CI:1.00-1.02)、超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)(OR=3.24,95%CI:1.12-9.37)、中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)(OR=1.26,95%CI:1.03-1.56)、HIV感染者/艾滋病患者确诊时间5-<10年(OR=13.28,95%CI:1.59-111.00)、接受ART时间≥10年(OR=19.43,95%CI:1.13-334.07)、入院CD4^(+)T细胞≥350个/μl (OR=5.99, 95%CI:1.56-22.96)、低HIV-RNA (OR=4.63, 95%CI:1.47-14.63)是发生高血压的危险因素,入院高CD4^(+)T/CD8^(+)T比值(OR=0.24,95%CI:0.07-0.82)是其保护因素。结论 对规范接受ART的艾滋病患者定期监测危险因素,可早期预警高血压的发生。 Objective To explore the factors associated with co-occurrence of hypertension in human immunodeficiency virus(HIV)-infected people and acquired immunodeficiency syndrome(AIDS)patients receiving standard antiretroviral therapy(ART).Methods A case-control study was conducted,in which 216 HIV/AIDS patients with hypertension were selected as cases,and 216 HIV/AIDS patients without hypertension 1:1 matched by sex and age(±3 years)were selected as controls.Demographic data,clinical characteristics,inflammation indicators and other factors of the patients in the two groups were collected.Conditional logistic regression was used to analyze the factors associated with hypertension.Results Smoking(OR=5.03,95%CI:1.18-21.51),body mass index(BMI)≥24.0 kg/m^(2)(OR=3.55,95%CI:1.28-9.83),fasting blood glucose≥7.0 mmol/L(OR=5.47,95%CI:1.21-24.77),creatinine(OR=1.01,95%CI:1.00-1.02),high-sensitivity C-reactive protein(OR=3.24,95%CI:1.12-9.37),neutrophil to lymphocyte ratio(OR=1.26,95%CI:1.03-1.56),HIV/AIDS diagnosis within the prior 5-<10 years(OR=13.28,95%CI:1.59-111.00),ART duration≥10 years(OR=19.43,95%CI:1.13-334.07),CD4 cell counts≥350 cells/μl upon admission(OR=5.99,95%CI:1.56-22.96),and low HIV-RNA(OR=4.63,95%CI:1.47-14.63)were risk factors for co-occurrence of hypertension in HIV/AIDS cases,and high CD4/CD8 ratio upon admission(OR=0.24,95%CI:0.07-0.82)was a protective factor against hypertension in HIV/AIDS.Conclusions Regular monitoring of risk factors among HIV/AIDS patients receiving standard ART may facilitate early-warning of the occurrence of hypertension.
作者 欧阳辉 李红娟 付海艳 罗煜 刘俊 徐肇元 高瑞 段劲宇 毛亚超 杜映荣 OUYANG Hui;LI Hongjuan;FU Haiyan;LUO Yu;LIU Jun;XU Zhaoyuan;GAO Rui;DUAN Jinyu;MAO Yachao;DU Yingrong(The Third People's Hospital of Kunming,Kunming,Yunnan 650200,China;不详)
出处 《中国预防医学杂志》 CAS CSCD 北大核心 2023年第11期1204-1210,共7页 Chinese Preventive Medicine
基金 国家卫健委毒品依赖和戒治重点实验室项目(2020DAMOP-0013)。
关键词 人类免疫缺陷病毒 艾滋病 高血压 危险因素 炎症指标 Human immunodeficiency virus Acquired immunodeficiency syndrome Hypertension Risk factors Inflammation indicators
  • 相关文献

参考文献9

二级参考文献82

  • 1中国心血管健康与疾病报告编写组,王增武,胡盛寿.中国心血管健康与疾病报告2019概要[J].中华老年病研究电子杂志,2020(4):4-15. 被引量:918
  • 2李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:193
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5221
  • 4WHO STATEMENT. Accelerate expansion of antiretroviral therapy to all people living with HIV: WHO [ DB/OL ]. ( 2015-11-30 ) [ 2015-12-10 ]. http://www, who. int/mediacentre/news/statements/ 2015/antiretroviral-therapy-hiv/en/.
  • 5FAUCI A S, MARSTON H D. Ending the HIV-AIDSpandemic-follow the science [ J ]. N Engl J Meal, 2015, 373(23) :2197-2199.
  • 6FRIEDEN T R, FOTI K E, MERMIN J. Applying public health principles to the HIV epidemic-how are we doing? [J]. N Engl J Meal, 2015, 373(23): 2281-2287.
  • 7Insight Start Study Group, LUNDGREN J D, BABIKER A G, et al. Initiation of antiretroviral therapy in early asymptomatie HIV infection [ J ]. N Engl J Med, 2015, 373(9):795-807.
  • 8COHEN C, WOHL D, ARRIBAS JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/ emtrieitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-l-infected adults [ J ]. AIDS, 2014, 28 (7) :989-997.
  • 9COHEN C J, MOLINA J M, CASSETI3 I, et al. Week 96 efficacy and safety of rilpivirine in treatment- naive, HIV-1 patients in two Phase III randomized trials[J]. AIDS, 2013, 27(6) :939-950.
  • 10SARFO F S, SARFO M A, NORMAN B, et al. Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans : nevirapine's epitaph? [ J ]. PLoS ONE, 2014, 9 (4) : e94854.

共引文献5253

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部